Contrasting of Kezar Life Sciences Inc. (KZR) and Aridis Pharmaceuticals Inc. (NASDAQ:ARDS)

As Biotechnology companies, Kezar Life Sciences Inc. (NASDAQ:KZR) and Aridis Pharmaceuticals Inc. (NASDAQ:ARDS) are our subject to compare. And more specifically their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kezar Life Sciences Inc. N/A 0.00 19.68M -1.05 0.00
Aridis Pharmaceuticals Inc. 2.16M 32.16 23.74M -2.98 0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Kezar Life Sciences Inc. and Aridis Pharmaceuticals Inc.

Profitability

Table 2 provides us the net margins, return on equity and return on assets of both businesses.

Net Margins Return on Equity Return on Assets
Kezar Life Sciences Inc. 0.00% 0% 0%
Aridis Pharmaceuticals Inc. -1,099.07% 54.6% -91.5%

Liquidity

Kezar Life Sciences Inc. has a Current Ratio of 32.9 and a Quick Ratio of 32.9. Competitively, Aridis Pharmaceuticals Inc.’s Current Ratio is 5 and has 5 Quick Ratio. Kezar Life Sciences Inc.’s better ability to pay short and long-term obligations than Aridis Pharmaceuticals Inc.

Insider and Institutional Ownership

Kezar Life Sciences Inc. and Aridis Pharmaceuticals Inc. has shares held by institutional investors as follows: 47.5% and 0.7%. About 22.8% of Kezar Life Sciences Inc.’s share are held by insiders. Competitively, Aridis Pharmaceuticals Inc. has 17.8% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Kezar Life Sciences Inc. -9.94% 16.22% 45.19% 0% 0% 50.59%
Aridis Pharmaceuticals Inc. -25% -34.84% -41.67% 0% 0% -38.85%

For the past year Kezar Life Sciences Inc. has 50.59% stronger performance while Aridis Pharmaceuticals Inc. has -38.85% weaker performance.

Summary

Kezar Life Sciences Inc. beats on 6 of the 9 factors Aridis Pharmaceuticals Inc.

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Aridis Pharmaceuticals Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb that is in Phase IIa trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 to treat infections caused by A. baumannii; AR-201, an anti- respiratory syncytial virus F-protein mAb; and AR-501, an anti-infective therapy to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. Aridis Pharmaceuticals Inc. was founded in 2003 and is headquartered in San Jose, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.